Company intelligence / Profile preview
Medigen Biotechnology
Taipei City, Taiwanmedigen.com.tw ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Medigen has an active pipeline with clinical-stage assets in oncology and infectious diseases. Its COVID vaccine MVC-COV1901 is approved in Taiwan. OBP‑301 is in Phase II trials for solid tumors. Magicell-NK cell therapy is under clinical development for various cancers.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Cell therapyVaccineSmall moleculeRecombinant proteinGene therapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
MEDINET Co., Ltd. – exclusive license agreement for gamma-delta T cell therapies in TaiwanCellxpert Biotechnology – licensing of PI–88 outside TaiwanNKure – collaboration on NK cell therapies development in IndiaVaxess Technologies Inc. – co-development of combined vaccines
Beyond the preview
Go deeper on Medigen Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medigen Biotechnology.